High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy

Autor:	Lucillia Bezu, Guido Kroemer
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Biomarker cancer chemotherapy immunotherapy PD-1 blockade Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	OncoImmunology, Vol 13, Iss 1 (2024)
Druh dokumentu:	article
ISSN:	2162402X 2162-402X
DOI:	10.1080/2162402X.2024.2432059
Popis:	Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/cd36160065ac45ac8fb6223beeaf218d Zobrazit plný text záznamu View record in DOAJ